Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865139 | 0.92 | APLNR (0.37) | IDO1OPRK1 | |
| SCHEMBL17865173 | 0.90 | HDAC3 (0.40) | IDO1PAK1OPRK1 | |
| SCHEMBL17847555 | 0.89 | VCP (0.38) | OPRK1VCP | |
| SCHEMBL17847601 | 0.87 | PDE10A (0.38) | OPRK1 | |
| SCHEMBL19753629 | 0.86 | OPRK1 (0.37) | OPRK1 | |
| SCHEMBL19743155 | 0.79 | CCNE1 (0.36) | — | |
| SCHEMBL17847631 | 0.75 | ROCK2 (0.36) | — | |
| SCHEMBL17847596 | 0.75 | ROCK2 (0.36) | — | |
| SCHEMBL17847626 | 0.74 | MEN1 (0.38) | — | |
| SCHEMBL17844906 | 0.73 | PAK1 (0.45) | PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369130-B2 | Antibacterial compounds | AZIEN DE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2019-08-06 | — | — | US | disclosed |
| US-20170368017-A1 | ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-28 | — | — | US | disclosed |
| EP-3233826-A1 | NEW ANTIBACTERIAL COMPOUNDS | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096631-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10369130-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | HTR7 4513/4885IDO1 3131/4885PAK1 1437/4885 |
| US-20170368017-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | HTR7 4513/4885IDO1 3131/4885PAK1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.